| Revenue growth | Q2 -38% YoY; H1 -10% YoY |
|---|---|
| Margins | Adj. EBITDA Q2 -₹16.4 cr vs ₹23.9 cr; margin -57% |
| Demand visibility | Legacy prescriber pull; no dedicated field force yet |
Growth
Q2 revenue -38% YoY to ₹56.1 cr; H1 -10% to ₹159.9 cr. Q2 net loss ₹77.5 cr vs ₹24.2 cr profit.
Outlook
No numeric guidance. Full cost structure visible Q4 FY27/Q1 FY28; S&M build-out by Q4 FY27; debt reduction via capital infusion.
Risks
Transition costs, ₹68 cr exceptional items, ₹61 cr customer promotion-rights termination, ₹15 cr one-offs, Q2 EBITDA margin -57%.
Investor Presentation filed with BSE, NSE: NOVARTIND. Summary written with AI assistance from the document.
Evonile Pharma Ltd: key numbers
- Share price
- ₹1,719.85
- Market cap
- ₹4,246 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 43.4×Sector 41.3×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Evonile Pharma Ltd
All →Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.
Novartis India Management Change
Evonile Pharma (formerly Novartis India) appointed Mr. Gagan Sharma as President – Specialty Business and Senior Management Personnel effective October 26, 2026. The filing is a Regulation 30 senior management appointment intimation.
Novartis India Other Announcement
Novartis India Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations. This is a routine periodic disclosure.
Novartis India Annual General Meeting
Evonile Pharma (fka Novartis India) issued a postal ballot notice for shareholder votes on ESOP 2026 grant to the MD & CEO and creation of charge on assets. E-voting runs 14 Oct–12 Nov 2026.